CCompany · Healthtech & Bio
Curapath
Curapath is a Spain-based CDMO (Contract Development and Manufacturing Organization) specializing in non-viral drug delivery systems, including lipid nanoparticles (LNPs), polymer nanoparticles, and polyamino acid-based conjugates for therapeutics and vaccines. Originally founded in 2013 in Paterna (Valencia) as Polypeptide Therapeutic Solutions, it was acquired by U.S. private equity firm Arcline Investment Management in 2021 and now also operates a Cambridge, MA office. Current leadership is led by CEO Philippe Clavel.
Founded
2013
Founders
0
News
0
Rounds
0
Investors
2
SectorsCDMO, Drug Delivery, Biotech, Pharma Services, Nanotechnology
Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO
Profile updated 29 Jul 2026
Founders
No names on record yet.
Global models 5
S
Sail Biomedicines
United States · sailbio.com ↗
Flagship Pioneering-backed RNA/programmable-medicines company built on LNP and other non-viral delivery platforms, similar core delivery-technology focus to Curapath.
$700M+Comparable
RReCode Therapeutics
United States · recodetx.com ↗
Develops proprietary lipid nanoparticle (non-viral) delivery platform for genetic medicines, directly comparable to Curapath's LNP/polymer delivery technology.
$260MComparable
OOrna Therapeutics
United States · ornatx.com ↗
Circular RNA therapeutics company relying on lipid nanoparticle non-viral delivery, matching Curapath's LNP formulation focus.
$301MComparable
R
Renagade Therapeutics
United States · renagadetx.com ↗
RNA medicines company built around a proprietary non-viral (LNP) delivery platform, similar technology base to Curapath.
$300MComparable
G
Generation Bio
United States · generationbio.com ↗
Genetic medicines company using a non-viral, closed-ended DNA and lipid nanoparticle delivery platform, closely matching Curapath's non-viral delivery specialty.
$227MComparable
Investors 2
AArcline Investment Management
CColumbus Venture Partners
columbusvp.com
Funding rounds
No announced rounds on record.
News & media
No coverage on record yet.